Advertisement

Related Videos

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement




Mar
24
Today In Oncology
Adding Tucatinib to First-Line Maintenance Therapy Delays Disease Progression in HER2-Positive Metastatic Breast Cancer
Awareness of Alcohol-Cancer Link Holds Steady Despite Omission in New US Dietary Guidelines
Myelofibrosis Treatment Landscape Is Poised for Change
AI Model Classifies Challenging Thymic Epithelial Tumors
Study Finds Inferior Survival Among Black Patients With AML, Independent of Cytogenetic Risk
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo